Latest data on GLP-1 drugs is that a large proportion of users are giving up taking them due to side effects. After all they were not designed for weight loss but to treat a serious disease and I suspect people with this disease will accept some side effects more than a healthy but over weight person. Therefore short term, GLP-1 drugs may start to lose their attractiveness but my core opinion remains unchanged - longer-term there are better weight loss drugs on the way and this will impact RMD. Remember RMD is a very specialized business. A strength and a weakness.
RMD Price at posting:
$25.44 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)